Ellen Holm Nielsen
Corporate Officer/Principal bei University of Southern Denmark
Aktive Positionen von Ellen Holm Nielsen
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| University of Southern Denmark | Corporate Officer/Principal | - | - |
| University of California, Berkeley | Corporate Officer/Principal | - | - |
| Albert Einstein College of Medicine, Inc. | Corporate Officer/Principal | 14.08.2009 | - |
| University of Copenhagen | Corporate Officer/Principal | - | - |
Karriereverlauf von Ellen Holm Nielsen
Ehemalige bekannte Positionen von Ellen Holm Nielsen
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
Profylakse ApS
 Profylakse ApS Pharmaceuticals: MajorHealth Technology Profylakse is a Danish biotech company, founded in 1999 by scientists from University of Southern Denmark. Profylakse has an experienced development team, working within microbiology, immunology and protein chemistry for 3 decades. Its focus is on the development of antiviral, not vaccines, especially against influenza and parainfluenza viruses. This has resulted in its antiviral recombinant SAP. Profylakse´s investor base is the Danish Technological Institute and the South Danish Innovations. | Direktor/Vorstandsmitglied | - | 22.11.2013 |
Statistik
International
| Dänemark | 4 |
| Vereinigte Staaten | 3 |
Operativ
| Corporate Officer/Principal | 4 |
| Director/Board Member | 1 |
Sektoral
| Consumer Services | 5 |
| Health Technology | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 1 |
|---|---|
Profylakse ApS
Profylakse ApS Pharmaceuticals: MajorHealth Technology Profylakse is a Danish biotech company, founded in 1999 by scientists from University of Southern Denmark. Profylakse has an experienced development team, working within microbiology, immunology and protein chemistry for 3 decades. Its focus is on the development of antiviral, not vaccines, especially against influenza and parainfluenza viruses. This has resulted in its antiviral recombinant SAP. Profylakse´s investor base is the Danish Technological Institute and the South Danish Innovations. | Health Technology |
- Börse
- Insiders
- Ellen Holm Nielsen
- Erfahrung
